All In Biotech

Drug Trial Radar · NCT06634420

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

80

Actual

Start

Jan 15, 2025

Primary completion

Feb 10, 2026

Study completion Sep 2027

Sponsor

Lead sponsor
Intellia TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

Conditions

  • Hereditary Angioedema

Interventions

  • NTLA-2002Biological

    CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration

  • Normal Saline IV AdministrationBiological

    The administration of intravenous (IV) normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-normalized number of Investigator-confirmed HAE attacksTime frame: From Week 5 through Week 28

Locations

29 sites in 9 countries. Site status is shown where the registry gives one.

  • Medical Research of Arizona

    Scottsdale, Arizona

  • University of California, San Diego (UCSD)

    San Diego, California

  • Raffi Tachdjian MD, Inc

    Santa Monica, California

  • Allergy & Asthma Clinical Research

    Walnut Creek, California

  • IMMUNOe International Research Centers

    Centennial, Colorado

  • Asthma & Allergy Associates

    Colorado Springs, Colorado

  • University of South Florida

    Tampa, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University in St. Louis

    St Louis, Missouri

  • NYU Langone Health - Long Island

    Mineola, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • AARA Research Center

    Dallas, Texas

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • University of Alberta

    Edmonton, Alberta, Canada

  • Ottawa Allergy Research Corporation

    Ottawa, Ontario, Canada

  • CHU Grenoble-Alpes - Hopital Michallon

    Grenoble, France

  • CHU de Lille - Hopital Claude Huriez

    Lille, France

  • AP-HM - Hopital de la Timone

    Marseille, France

  • Charite Universitaetsmedizin Berlin

    Berlin, Germany

  • Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet

    Frankfurt, Germany

  • Medizinische Hochschule Hannover (MHH)

    Hanover, Germany

  • Amsterdam UMC - Locatie AMC

    Amsterdam, Netherlands

  • New Zealand Clinical Research (NZCR)

    Auckland, New Zealand

  • University of Cape Town - Lung Institute - Lung Clinical Research Unit

    Cape Town, South Africa

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.